Jason Orestes

Jason Orestes is a writer for TheStreet and a former analyst for Interactive Brokers and PE firm Broadtree Partners. He often utilizes ratio analysis to seek out value and well-priced growth opportunities. He also breaks down the unique impacts macro events will have on certain companies and sectors. His work can also be found on Seeking Alpha.

Recent Articles By The Author

Walmart Is a Good Buy Whether You Expect a Recession or a Continued Bull Market

Walmart Is a Good Buy Whether You Expect a Recession or a Continued Bull Market

Walmart reported stellar earnings last month and has outpaced the market so far this year. But what if the recession everyone's concerned about comes to life? Doesn't matter, Walmart is still a buy.

Bet on an Infrastructure Bill Before the 2020 Election; Here's How To Play It

Bet on an Infrastructure Bill Before the 2020 Election; Here's How To Play It

To help avoid a recession and bolster his reelection hopes, count on Trump pushing hard for a bipartisan infrastructure bill before the 2020 election. Here's what will do well when it happens.

As U.S. Interest Rates Head Lower, Here's What To Invest In

As U.S. Interest Rates Head Lower, Here's What To Invest In

It seems to be quite a safe bet that U.S. rates are headed lower. Here's what types of equities outperform when this happens.

What's the Fed Going to Do Next? Here's How to Prepare Whatever Course It Takes

What's the Fed Going to Do Next? Here's How to Prepare Whatever Course It Takes

There's been nonstop focus on trying to predict the Fed's next move. You're better off not trying to guess, however, and instead preparing for how each scenario will impact your portfolio.

Lam Research's Market Outperformance Should Only Continue

Lam Research's Market Outperformance Should Only Continue

The chip equipment maker has been outperforming the market and semiconductors broadly for the last three years, and there's no hint an end is in sight.

Shopify: Why You Should Stay on the Sidelines for Now

Shopify: Why You Should Stay on the Sidelines for Now

Shopify's growth is slowing and trades at a substantial premium. Eventually, the share price will come back down to earth and present a better entry opportunity.

Relax -- Your Stocks Can Handle China and a Weaponized Yuan

Relax -- Your Stocks Can Handle China and a Weaponized Yuan

The psychological impact of the yuan breaching 7 USD may actually augur well for U.S. stocks. And if China lets the yuan get even weaker, it may unite the rest of the world against it.

How to Invest in the Face of Deflation in the U.S. Economy

How to Invest in the Face of Deflation in the U.S. Economy

All central banks attempt to avoid deflation like the plague. But why exactly is it so detrimental and how can it affect your investments?

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?

3 Reasons the U.S. Dollar Will Continue to Get Stronger

3 Reasons the U.S. Dollar Will Continue to Get Stronger

The U.S. dollar has been one of the best performing currencies within the last year, but what has catalyzed this strength and will it continue?